Olverembatinib (HQP1351) in Combination with Lisaftoclax Overcomes Venetoclax Resistance in Preclinical Model of Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Xiong, Yan [1 ]
Liang, Zhiyan [2 ]
Min, Ping [1 ]
Wu, Bingxing [1 ]
Yu, Huidan [1 ]
Yang, Dajun [1 ,2 ,3 ]
Zhai, Yifan [1 ,2 ]
机构：
[1] Ascentage Pharm Suzhou Co Ltd, Suzhou, Peoples R China
[2] Ascentage Pharm Grp Inc, Rockville, MD USA
[3] Sun Yat sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-202699
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5777 / 5778
页数：2
相关论文
共 50 条
  • [31] Homoharringtonine Overcomes Drug Resistance and Synergises with Venetoclax in Acute Myeloid Leukemia Via Inhibiting Protein Synthesis
    Kwok, Tsz Ho
    Wong, Kelvin King Wai
    Lam, Wing
    Dang, Chee Chean
    Zeng, Xiaoyuan
    Leung, Wing Yan
    Ng, Timothy Chi Chun
    Leung, Anskar
    Man, Cheuk Him
    BLOOD, 2022, 140 : 11540 - 11540
  • [32] Continous exposure to methothrexate (MTX) overcomes resistance in childhood acute myeloid leukemia (AML) in vitro
    Rots, MG
    Zwaan, CM
    Pieters, R
    Kaspers, GJL
    Noordhuis, P
    van Zantwijk, CH
    Creutzig, U
    Peters, GJ
    Veerman, AJP
    Jansen, G
    PEDIATRIC RESEARCH, 1999, 45 (05) : 775 - 775
  • [33] Continuous Exposure to Methotrexate (MTX) Overcomes Resistance in Childhood Acute Myeloid Leukemia (AML) in Vitro
    M G Rots
    Ch M Zwaan
    R Pieters
    G J L Kaspers
    P Noordhuis
    C H Van Zantwijk
    U Creutzig
    G J Peters
    A J P Veerman
    G Jansen
    Pediatric Research, 1999, 45 : 775 - 775
  • [34] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
    Qian Jiang
    Zongru Li
    Yazhen Qin
    Weiming Li
    Na Xu
    Bingcheng Liu
    Yanli Zhang
    Li Meng
    Huanling Zhu
    Xin Du
    Suning Chen
    Yang Liang
    Yu Hu
    Xiaoli Liu
    Yongping Song
    Lichuang Men
    Zi Chen
    Qian Niu
    Hengbang Wang
    Ming Lu
    Dajun Yang
    Yifan Zhai
    Xiaojun Huang
    Journal of Hematology & Oncology, 15
  • [35] Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
    Qian Jiang
    Zongru Li
    Yazhen Qin
    Weiming Li
    Na Xu
    Bingcheng Liu
    Yanli Zhang
    Li Meng
    Huanling Zhu
    Xin Du
    Suning Chen
    Yang Liang
    Yu Hu
    Xiaoli Liu
    Yongping Song
    Lichuang Men
    Zi Chen
    Qian Niu
    Hengbang Wang
    Ming Lu
    Dajun Yang
    Yifan Zhai
    Xiaojun Huang
    Journal of Hematology & Oncology, 16
  • [36] A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
    Jiang, Qian
    Li, Zongru
    Qin, Ya-Zhen
    Zhao, Ting
    Liu, Bingcheng
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiao-Jun
    BLOOD, 2022, 140
  • [37] Synergy of tyrosine kinase inhibitor HQP1351 and MDM2-P53 antagonist, APG-115, in preclinical models of FLT3 mutant and TP53 wild-type acute myeloid leukemia
    Fang, Douglas D.
    Tang, Qiuqiong
    Wang, Qixin
    Li, Na
    Fang, Xu
    Gu, Jiaxing
    Kong, Yanhui
    Rong, Tao
    Wang, Guangfeng
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2020, 80 (16)
  • [38] A New Class of Synthetic Type-B Polycyclic Polyprenylated Acylphloroglucinols (PPAP-B) Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
    Kampa, Leonie Elisabeth
    Bleisch, Anton
    Peslalz, Philipp
    Schittenhelm, Marcus Matthias
    Plietker, Bernd
    Kampa-Schittenhelm, Kerstin Maria
    BLOOD, 2023, 142
  • [39] Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
    Garciaz, Sylvain
    Saillard, Colombe
    Hicheri, Yosr
    Hospital, Marie-Anne
    Vey, Norbert
    CANCERS, 2021, 13 (22)
  • [40] Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
    Claudie Bosc
    Estelle Saland
    Aurélie Bousard
    Noémie Gadaud
    Marie Sabatier
    Guillaume Cognet
    Thomas Farge
    Emeline Boet
    Mathilde Gotanègre
    Nesrine Aroua
    Pierre-Luc Mouchel
    Nathaniel Polley
    Clément Larrue
    Eléonore Kaphan
    Muriel Picard
    Ambrine Sahal
    Latifa Jarrou
    Marie Tosolini
    Florian Rambow
    Florence Cabon
    Nathalie Nicot
    Laura Poillet-Perez
    Yujue Wang
    Xiaoyang Su
    Quentin Fovez
    Jérôme Kluza
    Rafael José Argüello
    Céline Mazzotti
    Hervé Avet-Loiseau
    François Vergez
    Jérôme Tamburini
    Jean-Jacques Fournié
    Ing S. Tiong
    Andrew H. Wei
    Tony Kaoma
    Jean-Christophe Marine
    Christian Récher
    Lucille Stuani
    Carine Joffre
    Jean-Emmanuel Sarry
    Nature Cancer, 2021, 2 : 1204 - 1223
12345